ATE125821T1 - Vakzin gegen hepatitis b. - Google Patents

Vakzin gegen hepatitis b.

Info

Publication number
ATE125821T1
ATE125821T1 AT91907263T AT91907263T ATE125821T1 AT E125821 T1 ATE125821 T1 AT E125821T1 AT 91907263 T AT91907263 T AT 91907263T AT 91907263 T AT91907263 T AT 91907263T AT E125821 T1 ATE125821 T1 AT E125821T1
Authority
AT
Austria
Prior art keywords
vhbsag
vaccine against
against hepatitis
fragment
antibodies
Prior art date
Application number
AT91907263T
Other languages
English (en)
Inventor
Carman Wiliam Frederick
Thomas Howard Christopher
Original Assignee
Imperial College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial College filed Critical Imperial College
Application granted granted Critical
Publication of ATE125821T1 publication Critical patent/ATE125821T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT91907263T 1990-03-29 1991-03-25 Vakzin gegen hepatitis b. ATE125821T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909007024A GB9007024D0 (en) 1990-03-29 1990-03-29 Novel vaccine

Publications (1)

Publication Number Publication Date
ATE125821T1 true ATE125821T1 (de) 1995-08-15

Family

ID=10673467

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91907263T ATE125821T1 (de) 1990-03-29 1991-03-25 Vakzin gegen hepatitis b.

Country Status (16)

Country Link
US (1) US6099840A (de)
EP (1) EP0522030B1 (de)
JP (2) JP2876091B2 (de)
KR (1) KR100208129B1 (de)
AT (1) ATE125821T1 (de)
CA (1) CA2078694C (de)
DE (1) DE69111801T2 (de)
DK (1) DK0522030T3 (de)
ES (1) ES2075440T3 (de)
GB (1) GB9007024D0 (de)
GR (1) GR3017804T3 (de)
IE (1) IE67877B1 (de)
NZ (1) NZ237611A (de)
PT (1) PT97159B (de)
WO (1) WO1991014703A1 (de)
ZA (1) ZA912305B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565354A (en) * 1986-09-05 1996-10-15 Sandoz Ltd. Production of human monoclonal antibodies specific for hepatitis B surface antigen
CA2067003A1 (en) * 1991-04-29 1992-10-30 Peter J. Kniskern Hbsag escape mutant vaccine
EP0533263A3 (en) * 1991-09-20 1994-06-08 Merck & Co Inc A multivalent hepatitis b virus vaccine
WO1993012815A1 (fr) * 1991-12-27 1993-07-08 Gensci Limited Procede d'obtention d'un antigene de surface recombine de l'hepatite b, antigene et vaccin a base de celui-ci
EP0565794A1 (de) * 1992-04-14 1993-10-20 British Biotech Pharmaceuticals Limited Induktion von CTL-Antworten
SG48365A1 (en) 1992-05-23 1998-04-17 Smithkline Beecham Biolog Combined vaccines comprising hepatitis b surface antigen and other antigens
US5750106A (en) * 1993-01-28 1998-05-12 Novartis Ag Human monoclonal antibodies to cytomegalovirus
US6030616A (en) * 1993-03-24 2000-02-29 Imperial College Of Science, Technology & Medicine Hepatitis B escape mutant specific binding molecules
WO1994021812A2 (en) * 1993-03-24 1994-09-29 Imperial College Of Science, Technology & Medicine Hepatitis b escape mutant specific binding molecules
US5595739A (en) * 1993-05-07 1997-01-21 Abbott Laboratories Hepatitis B virus mutants, reagents and methods for detection
GB9401987D0 (en) * 1994-02-02 1994-03-30 Imperial College Modified nucleic acid
GB9623233D0 (en) 1996-11-07 1997-01-08 Smithkline Beecham Biolog Vaccine composition
EP0919568A1 (de) 1997-12-01 1999-06-02 Sorin Diagnostics S.r.l. Fluchtmutanten des Oberflächenantigens des Hepatitis B Virus
CA2332173A1 (en) * 1998-06-19 1999-12-23 Government Of The Republic Of Singapore A vaccine-induced hepatitis b viral strain and uses thereof
KR100629028B1 (ko) 1998-10-16 2006-09-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 애쥬번트 시스템 및 백신
AUPP967999A0 (en) 1999-04-09 1999-05-06 North Western Health Care Network Viral variants
UA79735C2 (uk) * 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
FR2815634B1 (fr) * 2000-10-20 2003-10-31 Biomerieux Sa Anticorps monoclonaux diriges contre des virus de l'hepatite b
JP4430677B2 (ja) 2004-09-22 2010-03-10 株式会社先端生命科学研究所 Ｂ型肝炎ウイルスｓ抗原の検出法
CA2605179A1 (en) * 2005-04-18 2006-10-26 Novartis Vaccines And Diagnostics, Inc. Expressing hepatitis b virus surface antigen for vaccine preparation
GB0514578D0 (en) 2005-07-15 2005-08-24 Orthotics Online Ltd Copper orthotic
EP2441469A1 (de) 2006-03-14 2012-04-18 Oregon Health and Science University Verfahren zur Erzeugung einer Immunantwort auf Tuberculosis
JP5814507B2 (ja) 2006-09-07 2015-11-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
WO2008106551A2 (en) 2007-02-28 2008-09-04 The Govt. Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Serv. Brachyury polypeptides and methods for use
JP2010525035A (ja) 2007-05-02 2010-07-22 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
WO2009143524A2 (en) 2008-05-23 2009-11-26 The Regents Of The University Of Michigan Nanoemulsion vaccines
WO2010099472A2 (en) 2009-02-27 2010-09-02 The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services Spanx-b polypeptides and their use
GB201105981D0 (en) 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
AU2013287516B2 (en) * 2012-07-10 2016-07-07 Green Cross Corporation An antibody composition for prevention or treatment of mutant hepatitis B virus infection
WO2014043518A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
RU2603729C2 (ru) * 2015-04-24 2016-11-27 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантная вакцина для профилактики вирусного гепатита в (варианты)
RU2586513C1 (ru) * 2015-04-24 2016-06-10 Закрытое акционерное общество научно-производственная компания "Комбиотех" РЕКОМБИНАНТНЫЙ ШТАММ ДРОЖЖЕЙ Hansenula polymorpha - ПРОДУЦЕНТ МУТАНТНОГО ПОВЕРХНОСТНОГО АНТИГЕНА ВИРУСА ГЕПАТИТА В (ВАРИАНТЫ)
EP4137150A1 (de) 2015-08-03 2023-02-22 The United States of America, as represented by the Secretary, Department of Health and Human Services Brachyury-deletionsmutanten, nichthefevektoren zur codierung von brachyury-deletionsmutanten und verwendung davon

Also Published As

Publication number Publication date
ZA912305B (en) 1992-01-29
CA2078694A1 (en) 1991-09-30
AU642729B2 (en) 1993-10-28
GR3017804T3 (en) 1996-01-31
IE67877B1 (en) 1996-05-01
EP0522030A1 (de) 1993-01-13
DK0522030T3 (da) 1995-12-27
IE911022A1 (en) 1991-10-09
US6099840A (en) 2000-08-08
WO1991014703A1 (en) 1991-10-03
ES2075440T3 (es) 1995-10-01
GB9007024D0 (en) 1990-05-30
NZ237611A (en) 1994-09-27
PT97159A (pt) 1991-12-31
JP2876091B2 (ja) 1999-03-31
JPH11178591A (ja) 1999-07-06
CA2078694C (en) 1998-10-27
PT97159B (pt) 1998-07-31
JPH05505805A (ja) 1993-08-26
KR100208129B1 (ko) 1999-07-15
JP3049018B2 (ja) 2000-06-05
AU7561391A (en) 1991-10-21
EP0522030B1 (de) 1995-08-02
DE69111801T2 (de) 1995-12-14
DE69111801D1 (de) 1995-09-07

Similar Documents

Publication Publication Date Title
DE69111801D1 (de) Vakzin gegen hepatitis b.
MX9603182A (es) Vacuna de hepatitis b.
DK0527815T3 (da) Hepatitis C-virus-epitop
BR9306820A (pt) Conjugado de um antígeno fracamente imunogênico e um veículo peptideo sintetico vacina processos para melhorar a imunogenicidade de uma molecula de antigeno fracamente imunogenico e para imunizar um hospedeiro mamífero
CA2103887A1 (en) Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
PT101052A (pt) Proteinas hibridas uteis na preparacao de vacinas
BR9106220A (pt) Antigenos sinteticos para a deterccao de anticorpos para o virus da hepatite c.
KR910019641A (ko) 사람 유두종 바이러스(hpv) 18의 단백질상의 혈청 반응성 에피토프
NZ535908A (en) HIV regulatory and auxilliary peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
ATE312846T1 (de) Monoklonale antikörper gegen hepatitis b virus
DE59309950D1 (de) HCV Peptidantigene und Verfahren zur Bestimmung von HCV
KR920002629A (ko) B형 간염 코어 항원의 아미노산 잔기 서열
DE69011122D1 (de) Rubella-e1 und c peptide.
WO2002051865A3 (fr) Antigenes proteiques inducteurs d'anticorps neutralisant le virus vih
BRPI0204599B8 (pt) kit para a detecção simultânea de anticorpo para hcv e antígeno de hcv
AU1146692A (en) Recombinant proteins with the immunoreactivity of hepatitis b virus e antigen (hbeag), a process for the preparation thereof and the use thereof in immunoassays and vaccines

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee